Cargando…
Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1
Crigler‐Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked decrease in uridine‐diphosphate‐glucuronosyltransferase (UGT1A1) enzyme activity. Delivery of hUGT1A1‐modRNA (a modified messenger RNA encoding for UGT1A1) as a lipid nanoparticle is anticipated to restore hepa...
Autores principales: | Apgar, Joshua F., Tang, Jian‐Ping, Singh, Pratap, Balasubramanian, Nanda, Burke, John, Hodges, Michael R., Lasaro, Melissa A., Lin, Lin, Miliard, Bjorn L., Moore, Kristi, Jun, Lucy S., Sobolov, Susan, Wilkins, Anna Katharina, Gao, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391595/ https://www.ncbi.nlm.nih.gov/pubmed/29637732 http://dx.doi.org/10.1002/psp4.12301 |
Ejemplares similares
-
CORRIGENDUM: Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1
por: Apgar, J.F., et al.
Publicado: (2020) -
Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome
por: Collaud, Fanny, et al.
Publicado: (2018) -
Crigler-Najjar syndrome type 2: Novel UGT1A1 mutation
por: Nair, Karippoth Mohandas, et al.
Publicado: (2012) -
Novel combined UGT1A1 mutations in Crigler Najjar Syndrome type I
por: Abdellaoui, Nawel, et al.
Publicado: (2022) -
Spectrum of UGT1A1 Variations in Chinese Patients with Crigler-Najjar Syndrome Type II
por: Li, Lufeng, et al.
Publicado: (2015)